Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012.

Lomas J, Martin S, Claxton K.

Value Health. 2019 Sep;22(9):995-1002. doi: 10.1016/j.jval.2019.04.1926. Epub 2019 Jun 18.

PMID:
31511189
2.

The Value of Further Research: The Added Value of Individual-Participant Level Data.

Saramago P, Espinoza MA, Sutton AJ, Manca A, Claxton K.

Appl Health Econ Health Policy. 2019 Jun;17(3):273-284. doi: 10.1007/s40258-019-00462-x.

PMID:
30671918
3.

Appraising the value of evidence generation activities: an HIV modelling study.

Woods B, Rothery C, Anderson SJ, Eaton JW, Revill P, Hallett TB, Claxton K.

BMJ Glob Health. 2018 Dec 7;3(6):e000488. doi: 10.1136/bmjgh-2017-000488. eCollection 2018.

4.

Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data.

Ochalek J, Lomas J, Claxton K.

BMJ Glob Health. 2018 Nov 5;3(6):e000964. doi: 10.1136/bmjgh-2018-000964. eCollection 2018. Erratum in: BMJ Glob Health. 2019 Jun 4;4(3):e000964corr1.

5.

Comment: Positive tails and normative dogs.

Claxton K.

Health Econ. 2018 Oct;27(10):1425-1427. doi: 10.1002/hec.3802. Epub 2018 Aug 2. No abstract available.

6.

Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses.

Soares MO, Sharples L, Morton A, Claxton K, Bojke L.

Value Health. 2018 Jun;21(6):715-723. doi: 10.1016/j.jval.2018.01.019. Epub 2018 Apr 25. Review.

7.

Discounting in Economic Evaluations.

Attema AE, Brouwer WBF, Claxton K.

Pharmacoeconomics. 2018 Jul;36(7):745-758. doi: 10.1007/s40273-018-0672-z. Review.

8.

Supporting the development of a health benefits package in Malawi.

Ochalek J, Revill P, Manthalu G, McGuire F, Nkhoma D, Rollinger A, Sculpher M, Claxton K.

BMJ Glob Health. 2018 Apr 9;3(2):e000607. doi: 10.1136/bmjgh-2017-000607. eCollection 2018.

9.

The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality.

Claxton K, Lomas J, Martin S.

Health Econ. 2018 Jun;27(6):1017-1023. doi: 10.1002/hec.3650. Epub 2018 Apr 2.

10.

Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts.

Lomas J, Claxton K, Martin S, Soares M.

Value Health. 2018 Mar;21(3):266-275. doi: 10.1016/j.jval.2017.10.006. Epub 2018 Jan 4.

11.

Social value and individual choice: The value of a choice-based decision-making process in a collectively funded health system.

Espinoza MA, Manca A, Claxton K, Sculpher M.

Health Econ. 2018 Feb;27(2):e28-e40. doi: 10.1002/hec.3559. Epub 2017 Oct 4.

12.

A Cost-Effectiveness Analysis of Intradiscal Electrothermal Therapy Compared with Circumferential Lumbar Fusion.

Stamuli E, Kesornsak W, Grevitt MP, Posnett J, Claxton K.

Pain Pract. 2018 Apr;18(4):515-522. doi: 10.1111/papr.12641. Epub 2017 Nov 3.

13.

How to design the cost-effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework.

Johannesen KM, Claxton K, Sculpher MJ, Wailoo AJ.

Health Econ. 2018 Feb;27(2):e41-e54. doi: 10.1002/hec.3561. Epub 2017 Aug 22.

14.

The Value of Innovation [Internet].

Claxton K, Longo R, Longworth L, McCabe C, Wailoo A.

London: National Institute for Health and Care Excellence (NICE); 2009 May 22.

15.

A Pilot Study of Value of Information Analysis to Support Research Recommendations for NICE [Internet].

Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z, Tappenden P, Wailoo A.

London: National Institute for Health and Care Excellence (NICE); 2005 Jun.

16.

Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions.

Sculpher M, Claxton K, Pearson SD.

Value Health. 2017 Feb;20(2):234-239. doi: 10.1016/j.jval.2016.11.021.

17.

Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs.

Rothery C, Claxton K, Palmer S, Epstein D, Tarricone R, Sculpher M.

Health Econ. 2017 Feb;26 Suppl 1:109-123. doi: 10.1002/hec.3467.

18.

Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.

Woods B, Revill P, Sculpher M, Claxton K.

Value Health. 2016 Dec;19(8):929-935. doi: 10.1016/j.jval.2016.02.017.

19.

The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought.

Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairns JA, Teerawattananon Y, Asfaw E, Lopert R, Culyer AJ, Walker DG.

Value Health. 2016 Dec;19(8):921-928. doi: 10.1016/j.jval.2016.04.015.

20.

A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions.

Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, Soares M, Spackman E, Rothery C.

Value Health. 2016 Sep - Oct;19(6):885-891. doi: 10.1016/j.jval.2016.03.2003. Epub 2016 May 11.

21.

Cancer Drugs Fund requires further reform.

Grieve R, Abrams K, Claxton K, Goldacre B, James N, Nicholl J, Parmar M, Parker C, Sekhon JS, Smeeth L, Spiegelhalter D, Sculpher M.

BMJ. 2016 Sep 27;354:i5090. doi: 10.1136/bmj.i5090. No abstract available.

22.

Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal.

Morton A, Adler AI, Bell D, Briggs A, Brouwer W, Claxton K, Craig N, Fischer A, McGregor P, van Baal P.

Health Econ. 2016 Aug;25(8):933-8. doi: 10.1002/hec.3366.

23.

International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework.

Malone DC, Berg NS, Claxton K, Garrison LP Jr, IJzerman M, Marsh K, Neumann PJ, Sculpher M, Towse A, Uyl-de Groot C, Weinstein MC.

J Clin Oncol. 2016 Aug 20;34(24):2936-7. doi: 10.1200/JCO.2015.64.4328. Epub 2016 Jun 13. No abstract available.

24.

Microarray testing in clinical diagnosis: an analysis of 5,300 New Zealand patients.

Mc Cormack A, Claxton K, Ashton F, Asquith P, Atack E, Mazzaschi R, Moverley P, O'Connor R, Qorri M, Sheath K, Love DR, George AM.

Mol Cytogenet. 2016 Mar 31;9:29. doi: 10.1186/s13039-016-0237-9. eCollection 2016.

25.

How to estimate the health benefits of additional research and changing clinical practice.

Claxton K, Griffin S, Koffijberg H, McKenna C.

BMJ. 2015 Nov 25;351:h5987. doi: 10.1136/bmj.h5987. No abstract available.

PMID:
26608737
26.

Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required.

McKenna C, Soares M, Claxton K, Bojke L, Griffin S, Palmer S, Spackman E.

Value Health. 2015 Sep;18(6):865-75. doi: 10.1016/j.jval.2015.05.003. Epub 2015 Aug 13.

27.

Methods to place a value on additional evidence are illustrated using a case study of corticosteroids after traumatic brain injury.

McKenna C, Griffin S, Koffijberg H, Claxton K.

J Clin Epidemiol. 2016 Feb;70:183-90. doi: 10.1016/j.jclinepi.2015.09.011. Epub 2015 Sep 18.

28.

Policy: Development goals should enable decision-making.

Shepherd K, Hubbard D, Fenton N, Claxton K, Luedeling E, de Leeuw J.

Nature. 2015 Jul 9;523(7559):152-4. doi: 10.1038/523152a. No abstract available.

PMID:
26156358
29.

Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.

Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M.

Health Technol Assess. 2015 Feb;19(14):1-503, v-vi. doi: 10.3310/hta19140.

30.

SNP Analysis and Whole Exome Sequencing: Their Application in the Analysis of a Consanguineous Pedigree Segregating Ataxia.

Nickerson SL, Marquis-Nicholson R, Claxton K, Ashton F, Leong IU, Prosser DO, Love JM, George AM, Taylor G, Wilson C, Gardner RJ, Love DR.

Microarrays (Basel). 2015 Oct 23;4(4):490-502. doi: 10.3390/microarrays4040490.

31.

Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?

Claxton K, Sculpher M, Palmer S, Culyer AJ.

Health Econ. 2015 Jan;24(1):1-7. doi: 10.1002/hec.3130.

PMID:
25488707
32.

The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application.

Espinoza MA, Manca A, Claxton K, Sculpher MJ.

Med Decis Making. 2014 Nov;34(8):951-64. doi: 10.1177/0272989X14538705. Epub 2014 Jun 18.

33.

When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.

Siebert U, Rochau U, Claxton K.

Z Evid Fortbild Qual Gesundhwes. 2013;107(9-10):575-84. doi: 10.1016/j.zefq.2013.10.020. Epub 2013 Nov 12. Review.

PMID:
24315327
34.

Developmental delay referrals and the roles of Fragile X testing and molecular karyotyping: a New Zealand perspective.

Doherty E, O'Connor R, Zhang A, Lim C, Love JM, Ashton F, Claxton K, Gregersen N, George AM, Love DR.

Mol Med Rep. 2013 May;7(5):1710-4. doi: 10.3892/mmr.2013.1386. Epub 2013 Mar 20.

PMID:
23525284
35.

Understanding Harris' understanding of CEA: is cost effective resource allocation undone?

Edlin R, McCabe C, Round J, Wright J, Claxton K, Sculpher M, Cookson R.

J Health Serv Res Policy. 2013 Jan;18(1):34-9. doi: 10.1258/jhsrp.2012.011057.

36.

When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.

Longworth L, Youn J, Bojke L, Palmer S, Griffin S, Spackman E, Claxton K.

Pharmacoeconomics. 2013 Feb;31(2):137-49. doi: 10.1007/s40273-012-0013-6. Review.

37.

What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.

Czoski-Murray C, Lloyd Jones M, McCabe C, Claxton K, Oluboyede Y, Roberts J, Nicholl JP, Rees A, Reilly CS, Young D, Fleming T.

Health Technol Assess. 2012 Dec;16(50):i-xvi, 1-159. doi: 10.3310/hta16500. Review.

38.

Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.

Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, Soares M, Spackman E, Youn J.

Health Technol Assess. 2012;16(46):1-323. doi: 10.3310/hta16460.

39.

Methods to assess cost-effectiveness and value of further research when data are sparse: negative-pressure wound therapy for severe pressure ulcers.

Soares MO, Dumville JC, Ashby RL, Iglesias CP, Bojke L, Adderley U, McGinnis E, Stubbs N, Torgerson DJ, Claxton K, Cullum N.

Med Decis Making. 2013 Apr;33(3):415-36. doi: 10.1177/0272989X12451058. Epub 2012 Aug 27.

PMID:
22927694
40.

Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions.

Walker S, Sculpher M, Claxton K, Palmer S.

Value Health. 2012 May;15(3):570-9. doi: 10.1016/j.jval.2011.12.013. Epub 2012 Mar 30.

41.

Real economics needs to reflect real decisions: a response to Johnson.

Sculpher M, Claxton K.

Pharmacoeconomics. 2012 Feb 1;30(2):133-6. doi: 10.2165/11596660-000000000-00000. No abstract available.

PMID:
22185184
42.

Methods to elicit experts' beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration.

Soares MO, Bojke L, Dumville J, Iglesias C, Cullum N, Claxton K.

Stat Med. 2011 Aug 30;30(19):2363-80. doi: 10.1002/sim.4288. Epub 2011 Jul 11.

PMID:
21748773
43.

A framework for addressing structural uncertainty in decision models.

Jackson CH, Bojke L, Thompson SG, Claxton K, Sharples LD.

Med Decis Making. 2011 Jul-Aug;31(4):662-74. doi: 10.1177/0272989X11406986. Epub 2011 May 20.

PMID:
21602487
44.

Budget allocation and the revealed social rate of time preference for health.

Paulden M, Claxton K.

Health Econ. 2012 May;21(5):612-8. doi: 10.1002/hec.1730. Epub 2011 Mar 24.

PMID:
21438069
45.

Addressing adoption and research design decisions simultaneously: the role of value of sample information analysis.

McKenna C, Claxton K.

Med Decis Making. 2011 Nov-Dec;31(6):853-65. doi: 10.1177/0272989X11399921. Epub 2011 Mar 10.

PMID:
21393558
46.

Discounting and decision making in the economic evaluation of health-care technologies.

Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ.

Health Econ. 2011 Jan;20(1):2-15. doi: 10.1002/hec.1612. Epub 2010 May 12.

PMID:
21154521
47.

Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods.

Sculpher M, Claxton K.

Health Econ. 2010 Oct;19(10):1132-6. doi: 10.1002/hec.1645. No abstract available.

PMID:
20662107
48.

Continuing the multiple sclerosis risk sharing scheme is unjustified.

McCabe C, Chilcott J, Claxton K, Tappenden P, Cooper C, Roberts J, Cooper N, Abrams K.

BMJ. 2010 Jun 3;340:c1786. doi: 10.1136/bmj.c1786. No abstract available.

PMID:
20522655
49.

Value for money and the Quality and Outcomes Framework in primary care in the UK NHS.

Walker S, Mason AR, Claxton K, Cookson R, Fenwick E, Fleetcroft R, Sculpher M.

Br J Gen Pract. 2010 May;60(574):e213-20. doi: 10.3399/bjgp10X501859. Review.

50.

Cost-effectiveness of enhanced external counterpulsation (EECP) for the treatment of stable angina in the United Kingdom.

McKenna C, Hawkins N, Claxton K, McDaid C, Suekarran S, Light K, Chester M, Cleland JG, Woolacott N, Sculpher M.

Int J Technol Assess Health Care. 2010 Apr;26(2):175-82. doi: 10.1017/S0266462310000073. Review.

PMID:
20392321

Supplemental Content

Loading ...
Support Center